Free shipping on all orders over $ 500

BX517

Cat. No. M7562

All AbMole products are for research use only, cannot be used for human consumption.

BX517  Structure
Size Price Availability Quantity
1mg USD 40 In stock
5mg USD 80 In stock
10mg USD 110 In stock
50mg USD 350 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

BX-517 blocks activation of Akt in tumor cells, is potent with IC50 of 0.1-1.0 μM. BX-517 blocks AKT2 activation in cells with submicromolar potency. BX-517 is 100-fold selective or better against a panel of seven additional Ser/Thr and Tyr kinases.

Chemical Information
Molecular Weight 282.3
Formula C15H14N4O2
CAS Number 850717-64-5
Solubility (25°C) 27 mg/mL in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Islam I, et al. Bioorg Med Chem Lett. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517.

Related PDK1 Products
OSU-03012

OSU-03012 is a novel and potent, blood-brain permeable inhibitor of PDK-1 with an IC50 of 5 µM.

GSK2334470

GSK2334470 is a highly specific and potent inhibitor of PDK1 with IC50 of 10 nM.

BX-795

BX795 is a potent and specific TBK1, IKKε and PDK-1 inhibitor with IC50 of 6 nM, 41 nM and 111 nM, respectively.

BX-912

BX912 is a selective potent PDK1 inhibitor with IC50 of 12 nM.

AZD7545

AZD7545 is a potent PDHK inhibitor with IC50 of 36.8 nM and 6.4 nM for PDHK1 and PDHK2, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: BX517 supplier, PDK1, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.